Semaglutide-Associated Skin Rashes
Ozempic (semaglutide) can cause skin rashes as part of reported hypersensitivity reactions. [1]
Serious hypersensitivity reactions have been reported with semaglutide, including rash and urticaria. [1]
Product-Label Evidence for Rash
Postmarketing semaglutide reactions include hypersensitivity reactions such as rash and urticaria. [1]
Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported, and semaglutide use should be discontinued if hypersensitivity reactions occur. [2]
Signs That Suggest Serious Hypersensitivity
Hypersensitivity reactions reported with semaglutide include rash and urticaria. [1]
If hypersensitivity reactions occur, discontinuation and prompt treatment per standard of care is recommended. [2]
Patients should not be restarted if there is a previous hypersensitivity to semaglutide. [2]
Rash Types Reported in Case Literature
Dermal hypersensitivity reactions associated with semaglutide have been reported in case reports of patients with skin findings consistent with drug hypersensitivity. [3]
Fixed drug eruption after semaglutide exposure has been reported as a delayed cutaneous hypersensitivity pattern. [4]
Frequency and Clinical Likelihood
The Ozempic label lists rash as a hypersensitivity reaction seen in postmarketing experience. [1]
The label does not provide a specific incidence rate for rash in placebo-controlled trials. [1]
Other Skin Reactions That May Occur
Injection-site reactions (e.g., injection-site discomfort and erythema) have been reported in placebo-controlled trials of Ozempic. [5]
Alopecia is also listed as a postmarketing reaction in the semaglutide product safety information. [1]
Practical Safety Guidance
Discontinuation of Ozempic is recommended if a hypersensitivity reaction occurs. [2]
Immediate medical evaluation is indicated for rash accompanied by systemic symptoms that suggest hypersensitivity, such as angioedema or difficulty breathing or swallowing. [6]
When to Seek Ongoing Medical Care
Persistent rash after semaglutide exposure should prompt clinical reassessment for drug reaction versus other etiologies. [6]
Cutaneous symptoms occurring during semaglutide therapy should be reported to the prescribing clinician as adverse effects. [6]